Latest News and Press Releases

PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

BALTIMORE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- November is Bladder Health Month, and the Urology Care Foundation (UCF), the official foundation of the American Urological Association, is lifting the...

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The...

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

BALTIMORE, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation (UCF)—the official foundation of the AUA—today announced Filipe de Carvalho,...

Reviews in Urology literature review of ZUSDURI (UNG-102) clinical trial program including ENVISION, OPTIMA II and the ATLAS clinical trials

KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead...

September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage...

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer...